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Influence of gastrectomy for stomach cancer on type 2 
diabetes mellitus for patients with a body mass index 
less than 30 kg/m
2
Kyu Chul Kang, Seok Hwan Shin, Yeon Ji Lee
1, Yoon Seok Heo
Departments of Surgery and 
1Family Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, Korea
Purpose: The impressive effect of LRYGBP on mildly obese patients (30 kg/m
2 ＜  BMI ＜  35 kg/m
2) with T2DM raises the ar-
gument for lowering the threshold for surgical intervention to non-obesity (BMI ＜  30 kg/m
2). The goal of this study was to 
evaluate the effect of gastrectomy on non-obese patients with T2DM and what preoperative clinical factors are associated 
with postoperative long term improvement. Methods: In this retrospective review, we analyzed the change in diabetic status 
in 75 patients with gastric cancer undergoing three different gastrectomies in a single institution from June 1996 to September 
2009. Pre- and postoperative fasting blood glucose, serum hemoglobin A1c and diabetic medication requirements were 
compared. The demographic data and other biochemical markers were also collected. Results: At an average follow-up of 
35.0 ± 25.9 months, we collected the data of 75 patients and evaluated the change of diabetes status. There was no resolution 
of diabetes in Billroth-I (B-I) group, and 45.2% of patients improved whereas the resolution rate of Billroth-II (B-II) and RY 
group was 22.2% and 23.5% and 85.2% and 88.2%, respectively. The improvement rate of diabetes mellitus (DM) status was 
7.46 times higher in B-II than in B-I patients. The method of reconstruction is the most powerful factor and severity and dura-
tion of diabetes showed significant clinical factors for the improvement of the disease after surgery. Conclusion: According to 
these results, foregut-bypass procedure may improve the type 2 DM better than can be explained by the effect of weight loss 
only. Diabetes remission is significantly higher in those with duration of diabetes less than 5 years.
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INTRODUCTION
The incidence of diabetes has been increasing globally 
at an alarming rate. The World Health Organization cur-
rently estimates that type 2 diabetes mellitus (T2DM) af-
fects 171 million people worldwide. With an increase in 
the number of obese children diagnosed with T2DM, it is 
predicted that more than 366 million people will be af-
fected by diabetes by year 2025 [1]. Such a rapid increase in 
diabetes is thought to be related to economic growth, 
westernization of life style, reduction of physical activity, 
emotional and physical stress and the extension of life 
expectancy. Although current antidiabetic treatment in-
cludes a variety of medications with enhanced efficacy, Kyu Chul Kang, et al.
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T2DM and the associated complications remain a sub-
stantial burden on the affected individuals and the society 
as a whole. 
T2DM is characterized by resistance to insulin signal-
ing, and is closely associated with obesity. The normal 
metabolic, neural and hormonal effects of the small intes-
tine on the pancreatic islets, referred as the enteroinsular ax-
is, are altered in patients with T2DM. When T2DM is asso-
ciated with morbid obesity, weight loss induced by bari-
atric surgical procedures has been shown to be extremely 
effective in improving or resolving diabetes [2-4]. 
Increased insulin sensitivity accompanying the weight 
loss appears to be the most likely explanation for the im-
provement in diabetes in these patients. However, im-
provement from diabetes following the procedures that 
bypass the foregut (i.e., stomach, duodenum, proximal je-
junum) such as gastric bypass or biliopancreatic diversion 
(BPD) seems to occur almost immediately after the sur-
gery, well before significant weight loss occurs [4], thus, 
suggesting additional mechanisms contributing to the 
rapid glycemic control. Gastric bypass has been shown to 
increase glucagon like peptide-1 (GLP-1)  and peptide YY 
(PYY) secretion [5,6] and decrease ghrelin level [7]. It is 
speculated that the “pro-incretin” effects of gastric bypass 
is related to the anatomical exclusion of the foregut from 
the nutrient passage. 
Amelioration of diabetes in patients undergoing sub-
total gastrectomy with Roux-en-Y (RY) reconstruction was 
reported in 1955 [8]. When the duodenum of a lean dia-
betic rat is bypassed surgically, normal glycemic control is 
restored [9]. These reports collectively suggest a glycemic 
control mechanism present in the foregut, and the ex-
clusion of this area from the nutrient passage may help im-
prove insulin sensitivity and diabetes. Several hypothesis 
have been proposed to explain the change of glycemic con-
trol after foregut bypass; foregut hypothesis, hindgut hy-
pothesis, anti-incretin hypothesis, etc.
Gastrectomy removes some portions of the stomach, 
and is indicated mostly in patients with gastric cancer and 
intractable ulcer disease. The gastrointestinal (GI) tract is 
reconstructed either by Billroth-I (B-I) or Billroth-II (B-II). 
While B-I gastrectomy preserves normal GI tract config-
uration, B-II gastrectomy limits food entrance into the 
duodenum. Based on the studies demonstrating a positive 
impact on diabetes through exclusion of the foregut, a dia-
betic patient undergoing B-II gastrectomy is suggested to 
improve from diabetes better than a B-I gastrectomy 
patient. It has not been shown, however, in a systematic 
way whether duodenal exclusion by B-II reconstruction 
improves diabetes when compared to B-I gastrectomy. 
Because of a high incidence of gastric cancer in Korea, a 
significant number of gastrectomies are performed 
annually. The aim of this study is to examine retro-
spectively and compare the progression of diabetes in 
non-obese patients undergoing gastrectomy.
METHODS
Patients
From June 1996 to September 2009, a total of 2,134 
Korean patients with stomach cancer underwent radical 
gastrectomy at Inha University Hospital (1,433 radical 
subtotal gastrectomies, 701 radical total gastrectomies). 
T2DM was noted in 169 patients (T2DM prevalence rate, 
7.9%). Diagnosis of T2DM was based on fasting blood glu-
cose (FBG) concentrations according to criteria estab-
lished by the American Diabetes Association [10]. In addi-
tion, patients with a known history of T2DM and using di-
abetic medication prior to surgery were also classified as 
having T2DM regardless of FBG or glycosylated hemoglo-
bin A1c (HbA1c) levels. Cancer of the stomach was estab-
lished by endoscopic biopsy in all cases. Three patients 
who had undergone intestinal resection due to other dis-
eases, six patients who had pancreatectomy due to gastric 
cancer invasion, one patient with body mass index (BMI) 
greater than 30, five patients with other endocrinopathies 
were excluded from the study. Five patients expired with-
in 6 months after operation, and 28 patients who died prior 
to the study were also excluded from the analysis. From 
the total of 121 patients during this period, 75 of these pa-
tients were evaluated for follow-up (62.0%). Clinical data 
collected for this study include age, sex, onset of DM, du-
ration of DM, pre- and postoperative FBG, BMI, serum 
HbA1c, diabetic medications, serum lipid levels. The 
study protocol was approved by the Institutional Review Improvement of T2DM after gastrectomy
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Board of Inha University Hospital (no. 08-115).
Operative method
Because all patients had stomach cancer, radical onco-
logic resection of stomach was performed. Radical onco-
logic gastric resection includes omentectomy, D2＋α 
lymph node dissection, and required negative resection 
margin in all cases. The operation methods carried out 
were the radical total gastrectomy and RY esoph-
agojejunostomy, radical subtotal gastrectomy B-I and rad-
ical subtotal gastrectomy B-II, with the operation chosen 
by location of cancer and operator's decision regardless of 
patient's diabetes status. In subtotal gastrectomy, approx-
imately 75% of distal stomach was resected and intestinal 
continuity was maintained by B-I or B-II reconstruction. In 
cases of close proximity of cancer to the pylorus, supra- 
and infrapyloric lymph node invasion, and excessive ten-
sion for B-I reconstruction, B-II reconstruction was per-
formed for intestinal continuity with 15 to 20 cm of affer-
ent limb. In total gastrectomy, RY esophagojejunostomy 
was performed with 40 cm Roux limb and 20 cm afferent 
limb. And in all patients, vagotomy was routinely per-
formed with the course of lymph node dissection.
Analytical methods
The established guidelines for determining diabetes 
resolution and improvement were followed. The parame-
ters monitored for this included the changes in medication 
requirements, fasting blood sugar (FBS) and HbA1c levels. 
Based on the changes in medication requirements, FBS 
and HbA1c levels, each patient's postoperative diabetes 
status was divided into resolved (degree 1, no medication, 
normal FBG and HbA1c ＜  6.0%), diet-controlled (degree 
2, no medications, 7% ＞  HbA1c ＞  6%, FBG ＞  125 mg/dL), 
improved (degree 3, fewer medications or normal FBG 
and HbA1c decrease ＞ 10% on same dose), unchanged 
(degree 4, unchanged medications and biochemical mark-
ers) or worsened (degree 5, more medications or increased 
FBG and HbA1c ＞ 10% on same dose). Additional pre- 
and postoperative clinical factors such as age, sex, onset of 
DM, duration of DM, pre- and postoperative FBG, BMI, se-
rum HbA1c, diabetic medications, serum lipid levels were 
compared and analyzed according to diabetes status.
Statistical analysis
All pre- and postoperative clinical indices were ana-
lyzed by Fisher's exact test. And the results of frequency 
across the three operation groups were analyzed by analy-
sis of variance. The proportion of weight loss and other bi-
ochemical markers was also calculated for each patient 
and compared to their change in diabetic status. Finally, 
multivariate analysis according to operative method ad-
justing other clinical factors was performed with logistic 
regression test. All statistical analysis was carried out us-
ing SPSS ver. 15 (SPSS Inc., Chicago, IL, USA). Results 
were considered statistically significant if P ＜  0.05.
RESULTS
Clinical characteristics of patients (Table 1)
Preoperative demographics, diabetes related bio-
chemical data for the total study population are listed in 
Tables 1. Fifty-four men and 21 women were included in 
the study (gender ratio, 2.6:1). The preoperative mean BMI 
was 23.8 ± 2.9 kg/m
2 (range, 15.6 to 29.9 kg/m
2) and mean 
HbA1c was 7.4 ± 1.6% (range, 4.8 to 12.2%). When stratified 
by the duration of DM, 33 patients (44%) had DM for less 
than 5 years, 18 patients (24%) for 5 to 10 years, and 24 pa-
tients (32%) had the diagnosis of DM for in excess of 10 
years. Nine patients (12%) had diet-controlled DM with no 
medications. While 51 patients (68%) were on oral hypo-
glycemics, 15 patients (20%) were noted to be insulin user. 
The diet control patients are included more in B-II and RY 
group. Higher percentage of the RY esophagojejunostomy 
patients were on oral agents than insulin when compared 
to the B-I or B-II patients (P = 0.022). There were no sig-
nificant differences of the other clinical parameters be-
tween the groups except severity of DM. 
The change of clinical factors after gastrectomy 
(Table 2)
The changes in the clinical indices (BMI, FBG, HbA1c, 
cholesterol levels) following gastrectomy were listed in 
Table 2. There was no difference in the duration of fol-
low-up periods (B-I, 35 months; B-II, 38 months; RY esoph-
agojejunostomy, 32 months). The decrease in BMI after RY Kyu Chul Kang, et al.
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Table 1. Preoperative characteristics of the patients by operative method
Characteristic Billroth-I (n = 31) Billroth-II (n = 27) RY (n = 17) P-value
Age (yr)      67 ± 10.6      68 ± 9.9      66 ± 8.8 0.791
Sex
  Male   21 (67.7)   19 (70.4)   14 (82.4) 0.573
  Female   10 (32.3)     8 (29.6)     3 (17.6) 0.573
DM onset age (yr)      55 ± 8.9      56 ± 9.8      56 ± 8.5 0.783
DM duration (yr)
  ＜5   11 (35.5)   15 (55.6)     7 (41.2) 0.543
  5-10     9 (29.0)     4 (14.8)     5 (29.4)
  ≥10   11 (35.5)     8 (29.6)     5 (29.4)
DM severity
  D-DM     1 (3.2)     4 (14.8)     4 (23.5) 0.022
a)
  O-DM   20 (64.5)   18 (66.7)   13 (76.5)
  I-DM   10 (32.3)     5 (18.5)     0 (0)
BMI   24.2 ± 2.4   23.8 ± 3.5   23.0 ± 2.7 0.396
FBG 164.0 ± 39.1 163.5 ± 60.9 162.6 ± 47.7 0.996
HbA1c     7.5 ± 1.4     7.2 ± 1.7     7.5 ± 1.7 0.787
Total cholesterol (mg/dL) 173.5 ± 38.5 178.6 ± 47.3 178.2 ± 46.7 0.890
Follow- up (mo)      35 ± 22.4      38 ± 30.2      32 ± 26.0 0.798
Values are presented as mean ± standard deviation or number (%).
RY, Roux-en Y esophagojejunostomy; DM, diabetes mellitus; D-DM, diet controlled DM; O-DM, oral hypoglycemics user; I-DM, insulin user; 
BMI, body mass index; FBG, fasting blood glucose; HbA1c, hemoglobin A1c.
a)Statistically significant Billroth-I and Billroth-II vs. RY by Fisher’s exact test.
Table 2. Changes of clinical factors after operations by reconstruction methods
Factor Billroth-I (n = 31)  Billroth-II (n = 27) RY (n = 17) P-value
Body mass index
  Pre-op   24.2 ± 2.4   23.8 ± 3.5   23.0 ± 2.7 0.037
a)
  Post-op   22.5 ± 2.3   22.2 ± 3.6   20.3 ± 2.6
Fasting blood glucose
  Pre-op 164.0 ± 39.1 163.5 ± 60.9 162.6 ± 49.1 0.518
  Post-op 140.6 ± 46.5 125.7 ± 38.5 122.1 ± 38.0
Hemoglobin A1c
  Pre-op     7.5 ± 1.4     7.2 ± 1.7     7.5 ± 1.7 0.403
  Post-op     7.3 ± 1.3     6.6 ± 1.3     6.6 ± 0.9
Total cholesterol
  Pre-op 173.5 ± 38.5 178.6 ± 47.3 178.2 ± 46.7 0.784
  Post-op 164.4 ± 49.0 155.4 ± 39.1 154.8 ± 33.3
RY, Roux-en Y esophagojejunostomy; Pre-op, preoperative; Post-op, postoperative.
a)Statistically significant Billroth-I and Billroth-II vs. RY by one way analysis of variance.
esophagojejunostomy is 11.7% and this is statistically 
greater compared to the weight loss resulting from the 
other operative methods. No other changes in the clinical 
indices were statistically significant.
Factors associated with postoperative DM impro-
vement (Table 3)
The factors associated with DM improvement were 
analyzed. The patients were stratified into two groups: 
those with improvements from preoperative DM vs. those 
with no improvements or worsening. When the patients 
DM duration was less than 5 years, improvement of DM 
was seen in 50% (26 patients). When the duration of DM 
was longer (more than 5 years), fewer number of patients 
achieved improvements from DM (15.4% and 34.6% for 5 
to 10 years and over 10 years groups respectively). No Improvement of T2DM after gastrectomy
thesurgery.or.kr 351
Table 3. Comparison between the improved and the unimproved
Improved 
DM (n = 52)
Unimproved 
DM (n = 23)
P-value
Age (yr)      67 ± 9.3       68 ± 11.1 0.502 
Sex
  Male   38 (73.1)    16 (69.6)  0.630 
  Female   14 (26.9)      7 (30.4) 
DM onset age (yr)      55 ± 9.0      56 ± 9.3 0.668 
DM duration (yr)
  ＜5   26 (50.0)      7 (30.4)  0.036
a)
  5-10     8 (15.4)    10 (43.5) 
  ≥10   18 (34.6)      6 (26.1) 
Pre-op BMI   23.7 ± 3.1    23.9 ± 2.5  0.761 
Pre-op FBG 163.9 ± 50.1  162.7 ± 45.8  0.928 
Pre-op HbA1c     7.3 ± 1.6      7.5 ± 1.4  0.775 
Pre-op total cholesterol 181.4 ± 44.0  165.0 ± 40.0  0.131 
ΔBMI     8.4 ± 7.6      6.6 ± 5.4  0.289 
ΔTotal cholesterol     8.9 ± 28.2     -3.5 ± 36.8  0.115 
Reconstruction method
  Billroth-I   14 (45.2)   17 (54.8) ＜0.001
a)
  Billroth-II   23 (85.2)     4 (14.8)
  RY   15 (88.2)     2 (11.8)
Follow-up (mo)    34.3 ± 26.7    37.6 ± 24.7  0.613
Values are presented as mean ± standard deviation or number (%).
DM, diabetes mellitus; Pre-op, preoperative; BMI, body mass 
index; FBG, fasting blood glucose; HbA1c, hemoglobin A1c; RY, 
Roux-en Y esophagojejunostomy.
a)Statistically significant improved DM vs. unimproved DM by 
Fisher’s exact test.
Table 4. Diabetes mellitus status after gastrectomy according to 
operative method
Billroth-I 
(n = 31)
Billroth-II 
(n = 27)
RY 
(n = 17)
P-value
Degree
  1   0 (0)   6 (22.2)   4 (23.5) ＜0.001
a)
  2   2 (6.5)   6 (22.2)   7 (41.2) 
  3 12 (38.7) 11 (40.7)   4 (23.5)
  4 11 (35.5)   3 (11.1)   2 (11.8)
  5   6 (19.4)   1 (3.7)   0 (0)
Improved
b) 14 (45.2) 23 (85.2)  15 (88.2) ＜0.001
a)
Unimproved
c)  17 (54.8)   4 (14.8)    2 (11.8)
Values are presented as number (%).
1, no medication, normal fasting blood glucose (FBG) and 
hemoglobin A1c (HbA1c); 2, no medication, 7% ＞  HbA1c ＞  6%, 
FBG  ＞ 125 mg/dL; 3, fewer medications or normal FBG and 
HbA1c decrease ＞  10% on same dose; 4, unchanged medications 
and biochemial markers; 5, more medications or increased FBG 
and HbA1c ＞  10% on same dose; RY, Roux-en Y esophagojejuno-
stomy.
a)Statistically significant Billroth-I and Billroth-II and RY by 
Fisber’s exact test. 
b)Degree 1 to 3. 
c)Degree 4 and 5.
Table 5. Postoperative diabetes mellitus (DM) status according to 
preoperative diabetes severity
Preoperative
DM severity
D-DM
(n = 9)
O-DM
(n = 51) 
I-DM
(n = 15)
P-value 
Degree
  1 4 (44.4)   6 (11.8)  0 (0) 0.001
a)
  2 4 (44.4)  11 (21.6)  0 (0) 
  3 0 (0) 18 (35.3)  9 (60.0)
  4 0 (0)  12 (23.5)  4 (26.7)
  5 1 (11.1)    4 (7.8)  2 (13.3)
Improved DM
b)  8 (88.9) 35 (68.6) 9 (60.0)  0.737
Unimproved DM
c) 1 (11.1) 16 (31.4)  6 (40.0)
Values are presented as number (%).
D-DM, diet controlled DM; O-DM, oral hypoglycemics user; 
I-DM, insulin user.
a)Statistically significant D-DM and O-DM vs. I-DM by Fisher’s
exact test. 
b)Degree 1 to 3. 
c)Degree 4 and 5.
changes or worsening of DM status were seen in 7 cases 
(30.4%), 10 cases (43.5), 6 cases (26%) respectively accord-
ing to the same period, and these values showed statistical 
significance (P = 0.036). Reconstruction method has stat-
istical significance between the improved and the unim-
proved (P ＜ 0.001), and this is the most powerful factor 
showing the difference between the two groups. There 
was no correlation between other preoperative clinical fac-
tors and the postoperative changes in diabetic status.
Procedure specific improvement of DM (Table 4)
The status of DM was studied before and after each spe-
cific procedure type. The degree of DM improvement was 
classified into five subgroups based on changes in FBS, 
HbA1c and medication requirements. No resolution of 
diabetes was noted in B-I patients. 45.2% of the B-I patients 
improved while DM of 54.8% of patients were unchanged 
or worsened. Contrast to B-I group, the resolution rate of 
B-II and RY esophagojejunostomy group was 22.5% and 
23.5% respectively, and 85.2% and 88.2% of patients 
showed improvements respectively (P ＜ 0.001). When 
duodenal bypass group (B-II and RY) was compared col-
lectively to the B-I patients significantly increased reso-
lution of DM (22.7%) and improvement (86.3%) were seen 
in the duodenal bypass group.Kyu Chul Kang, et al.
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Table 6. Multivariate analysis of the rate of improvement by 
operation method 
aPOR
95% Confidence interval
P-value
Lower limit Upper limit 
Billroth-I 1.00   ＜0.001
a)
Billroth-II 7.46   1.96  28.50 
RY 7.87   1.32  47.14 
aPOR, prevalence odds ratio adjusted for diabetes mellitus (DM) 
duration, DM severity, baseline hemoglobin A1c, age, sex, 
follow-up month and change of body mass index; RY, Roux-en Y 
esophagojejunostomy.
a)Statistically significant Billroth-I vs. Billroth-II and RY by logistic 
regression test.
Preoperative DM severity and postoperative im-
provement in DM status (Table 5)
Patients requiring insulin preoperatively showed no 
resolution of DM postoperatively. Only 60.0% of the in-
sulin users showed postoperative improvements; how-
ever, non insulin user showed 16.7% resolution and over-
all 71.7% of improvement rates (P = 0.001).
Multivariate analysis of procedure-specific im-
provements in DM (Table 6)
The postoperative changes in DM status following spe-
cific procedure (B-I, B-II, RY esophagojejunostomy) were 
compared by adjusting other clinical factors which may af-
fect diabetes control such as age, sex, DM duration, se-
verity, basal HbA1c and ΔBMI. The improvement rate of 
DM status was 7.46 and 7.87 times higher in B-II and RY 
esophagojejunostomy group respectively, than that in B-I 
group (Table 6). I would like to emphasize this result; B-II 
caused 7.46 fold improvement of T2DM although B-I and 
B-II resulted in similar weight loss. It should be explained.
DISCUSSION
T2DM affects a large population of patient across the 
world, and despite newer class of medications, it is a pro-
gressive disease leading to microvascular complications 
[11]. Although tight control of blood sugar may delay pro-
gression of the disease, an increased requirement of medi-
cations over time is commonly seen despite modest 
weight loss by diet and exercise even in patients with BMI 
less than 30 [12]. Morbidly obese patients with T2DM are 
noted to improve in their diabetes following successful 
weight loss surgery [13]. Weight loss achieved by these 
procedures is commonly believed to be the primary mech-
anism of improved insulin sensitivity, ultimately leading 
to improvement in T2DM. Our current data show that gas-
trectomy patients achieve significant improvement and/or 
resolution of T2DM. Furthermore B-II showed 7.46 times 
higher rate of improvement of T2D than B-I which lost 
similar body weight. The mechanism of improvement in 
T2DM in our study patients, thus, cannot be explained by 
simple weight loss.
Some of the bariatric procedures seem to achieve more 
profound improvement in T2DM than others. For exam-
ple, BPD has been shown to have a marked and sustained 
improvement in diabetes with 95 to 100% patients achiev-
ing resolution [14,15]. Similarly, gastric bypass induces 
resolution of diabetes in 83 to 85% patients in the long term 
[12,13,16]. In contrast to such bypass operations, purely re-
strictive bariatric procedures without alterations in in-
testinal continuity (i.e., vertical banded gastroplasty or 
gastric banding) achieve weight loss by limiting caloric in-
t a k e  b y  r e d u c i n g  t h e  s i z e  o f  t h e  f u n c t i o n a l  s t o m a c h .  
Improvement of T2DM following these procedures; how-
ever, seem to take a longer time and is far less than that 
seen in their bypass counterparts. The non-obese gas-
trectomy patients with duodenal bypass in this study (B-II 
and RY esophagojejunostomy) clearly improve more dra-
matically from T2DM when compared to B-I patients who 
continue to have passage of nutrients through the duo-
denum. Our data is thus consistent with the observation of 
enhanced DM improvements in obese patients under-
going the bariatric procedures with proximal small in-
testinal bypass. These findings suggest an additional 
mechanism(s) of glycemic control located in the proximal 
small bowel independent of weight changes.
Bypass of the proximal small intestine in bariatric pro-
cedures appears to cause profound postoperative alter-
ation in the secretion of GI peptides that affect insulin se-
cretion and insulin sensitivities. Examples of these pep-
tides include GLP-1, gastric inhibitory polypeptide (GIP) 
and PYY [17]. GLP-1, which is produced by L-cell in colon Improvement of T2DM after gastrectomy
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and ileum, induces proliferation of beta cells and pro-
motes insulin secretion in pancreas, and its secretion is in-
creased after gastric bypass surgery [18]. More rapid de-
livery of nutrients to the distal intestine due to the bypass 
anatomy is thought to be responsible for the enhanced 
GLP-1 secretion. Ghrelin, unlike GLP-1, decreases pancre-
atic insulin secretion while increasing food intake and GI 
motility. Ghrelin levels are known to decrease after gas-
trectomy or gastric bypass [7], may be contributing to the 
improvements of T2DM in our gastrectomy patients. The 
changes in ghrelin and GLP-1 levels were not measured in 
this retrospective study. All patients in this study under-
went radical gastrectomy which includes turncal vagot-
omy and omentectomy, both of which may also be con-
tributing to the improvement in diabetes in our patients.
Gastric cancer is one of the most prevalent cancers in 
Korea and Japan, and radical gastric resection is one of the 
most common types of surgery performed in East Asia. 
The preferred type of reconstruction following gas-
trectomy is a controversial subject. B-I anastomosis is con-
sidered the most physiologic reconstructive procedure, 
and it is the procedure of choice in distal gastric cancer 
patients. Based on our results of dramatic improvement in 
DM following duodenal bypass anatomy (7.46 fold im-
provement over B-I reconstruction), perhaps B-II or RY re-
construction should be considered in diabetic gastric can-
cer patients.
Most of the data in post-surgical T2DM improvement 
come from morbidly obese patients undergoing weight 
loss surgery even in Korea [19,20]. Less obese patients 
(BMI ＜ 35) with T2DM also seem to improve from dia-
betes after gastric bypass [21]. Our study shows significant 
improvement and/or resolution of T2DM is also achieved 
in patients who are not obese. The resolution rate of T2DM 
in non-obese Korean gastrectomy patients from this study 
seems somewhat lower than that seen in morbidly obese 
patients after bariatric surgery. T2DM in Korean patients 
is characterized by deterioration of early-phase insulin se-
cretion [22]. Therefore, T2DM in Korean patients appears 
to be associated with a severely impaired β-cell function, 
thus less likely to reverse compared to early insulin resist-
ance without significant beta-cell dysfunction seen in the 
Westerners [23]. Nevertheless, marked improvements in 
T2DM are seen our non-obese patients, particularly when 
the reconstruction is performed with duodenal bypass 
anatomy. Although tight glycemic control with medi-
cation (HbA1c less than 7%) has been shown to decrease 
the risk of microvascular complications associated with 
diabetes [24,25], such tight control with medication is dif-
ficult to achieve. Currently, no GI surgical procedure is ap-
proved to treat T2DM in non-obese patients. This is partic-
ularly important in East Asian countries where an alarm-
ing increase of T2DM is seen in patients who are non-obese 
but exhibit centrally obese anthropometry associated 
more with insulin secretory defects than insulin resistance 
[26]. The current data suggest the potential for effective 
surgical treatment for such non-obese T2DM patients.
There was no correlation between preoperative clinical 
factors with postoperative changes in diabetes status. The 
duration of preoperative T2DM and the duodenal bypass 
surgical anatomy were identified as the only significant 
factors that affect the postoperative diabetic status. 
Shorter preoperative DM duration appears to predict bet-
ter improvement in DM postoperatively. In addition, com-
plete resolution was not seen in insulin using patients, and 
only 60% of these patients achieved improvement. In con-
trast, 16.7% of the oral hypoglycemics users were able to 
achieve complete resolution along with additional 20.0% 
coming off all hypoglycemics, totally an overall improve-
ment rate of 71.7%. Regardless of the type of reconstruc-
tion, improvement from DM was less prominent in insulin 
using patients. These patients are likely to be hypo-
insulinemic as well as insulin resistant. The remaining 
pancreatic β-cell function may be an important determi-
nant of the likelihood of T2DM resolution following gas-
tric surgery [27]. Based on these, it appears that β-cell de-
terioration might be reversible at least early in the course 
of the disease and that it is best to intervene before perma-
nent islet cell injuries occur.
There are several limitations in our study. In this retro-
spective study, some of the important biochemical param-
eters could have been studied pre- and postoperative 
periods. These include levels of GLP-1, ghrelin, PYY and 
other pertinent diabetic markers. Formal oral glucose tol-
erance tests would have also strengthened this study. The 
patient follow-up was not established regularly as a pro-Kyu Chul Kang, et al.
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spective study, and thus, the data points are not precisely 
matched. The criteria of the improvement is arbitrary al-
though the criteria of the resolution matched the criteria of 
American Diabetes Association. That caused high rate of 
the improvement after surgery, comparing with other re-
ports [28,29]. Radical gastrectomy and reconstruction is 
quite different from the procedure employed in metabolic 
surgery (remaining stomach, long afferent limb etc.) The 
outcomes can be affected by many factors, such as disease 
stage, type of resection, extent of surgery, adjuvant treat-
ment, or postoperative weight change. Especially, the de-
gree of weight loss would be the most important factor 
which associated with control of diabetes. But my institute 
has two special surgeons for gastric cancer surgery, and 
they operated all patients enrolled. So the extent and type 
of operation can be consider as a standard method in gen-
eral without any intention because there was no idea of 
metabolic surgery at the time of the operation. As for the 
influence of adjuvant chemotherapy, the patients may be 
considered as the recovered because the recent patient was 
enrolled at 2 year after the surgery.
To improve the shortcomings of the current retro-
spective study, a prospective randomized study is being 
initiated with a regular long term follow-up protocol, col-
lection of more comprehensive data elements including all 
known incretins, diabetes markers, gut hormone levels.
Lastly, this paper has limited worth just to give a 
glimpse into the possibility of metabolic surgery although 
it does not have any datum of entroinsular physiology. Till 
now, T2DM is a progressive and dreadful disease, but it is 
notable finding that some surgical procedures can im-
prove the T2DM even in non-obese patients. Especially, we 
should take notice B-II showed 7.46 times higher rate of 
improvement than B-I which induced weight loss similar 
to B-II.
In summary, bypass of the foregut seems to have some 
mechanism of glycemic control beyond weight loss, which 
may mean that metabolic surgery can be a candidate to 
control T2DM.
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